Abstract
Neuroendocrine neoplasms (NEN) are increasingly diagnosed tumors with great clinical
and prognostic heterogeneity. One of the peculiarities of NEN is the presence of a
clinical hormone syndrome in about 30 % of cases. Somatostatin receptor imaging plays
an important role in the diagnosis of spreading and in the planning of therapy. NEN
patients should be co-supervised by specialized centers and if possible treated as
part of studies. In the case of NEN with no or only circumscribed metastases, complete
resection in curative intention is generally the highest therapeutic goal. Small neuroendocrine
tumors (NET) G1 of the stomach, duodenum and rectum can be curatively endoscopically
resected. In the case of a metastatic, non-curative disease, an antiproliferative
therapy with the aim of growth control takes place. In patients with functionally
active tumors, an antisecretory or symptomatic therapy is used to control the hormone
syndrome. The treatment of metastatic NET is often multimodal and must be established
by an experienced interdisciplinary team. The prognosis of NEN is mainly determined
by the stage at the time of diagnosis, tumor differentiation, grading and localization
of the primary tumor.
Neuroendokrine Neoplasien sind eine heterogene Gruppe von Tumoren, deren Diagnosehäufigkeit
seit Jahrzehnten stark zunimmt. Damit steigt bei oft gutem Langzeitüberleben die Wahrscheinlichkeit,
in der Praxis auf NEN-Patienten zu treffen. Dieser Beitrag gibt einen praxisnahen
Überblick über klinische, diagnostische und therapeutische Besonderheiten. Ausführlichere
Beschreibungen bietet die aktuelle deutsche S2k-Leitlinie Neuroendokrine Tumoren [1].
Schlüsselwörter
neuroendokrine Neoplasie - Somatostatin-Rezeptor-Bildgebung - Somatostatin-Analoga
- multimodale Therapie
Key words
neuroendocrine neoplasia - somatostatin receptor imaging - somatostatin analogs -
multimodal treatment
